Goserelin and leuprolide are both FDA-approved GnRH agonists with the same core mechanism — continuous dosing ultimately suppresses sex hormones after an initial flare. They're used in prostate and breast cancer, endometriosis, and related conditions. The main practical differences are formulation and delivery.
At a glance
| Goserelin | Leuprolide | |
|---|---|---|
| Class | GnRH agonist | GnRH agonist |
| Brand name | Zoladex | Lupron |
| FDA status | Approved | Approved |
| Formulation | Implant (under the skin) | Depot injection |
| Typical uses | Prostate/breast cancer, endometriosis | Prostate cancer, endometriosis, precocious puberty, IVF |
| Mechanism | Suppress hormones after initial flare | Suppress hormones after initial flare |
The bottom line
Bottom line: These are mechanistically the same tool — GnRH agonists that suppress sex hormones after a transient flare — and are often clinically interchangeable for overlapping indications. The differences are practical: goserelin is delivered as a small implant, leuprolide as a depot injection, with somewhat different approved-use lists. Both are approved prescription medicines.
Frequently asked questions
What's the difference between goserelin and leuprolide?
Both are FDA-approved GnRH agonists that suppress sex hormones after an initial flare. The main differences are delivery — goserelin is an implant (Zoladex), leuprolide a depot injection (Lupron) — and their specific approved indications.
Are Zoladex and Lupron interchangeable?
They share the same mechanism and overlap in uses like prostate cancer and endometriosis, so they are often clinically comparable, but the choice depends on formulation, indication, and clinician preference.
Do both cause an initial hormone flare?
Yes. As GnRH agonists, both briefly raise sex hormones before suppressing them. This flare is managed clinically, especially in hormone-sensitive cancers.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Cockshott ID. Clinical pharmacokinetics of goserelin. Clin Pharmacokinet. 2000. Peer-reviewed study
- Mitchell H. Goserelin ('Zoladex')--offering patients more choice in early breast cancer. Eur J Oncol Nurs. 2004. Peer-reviewed study
- Cheer SM, Plosker GL, Simpson D, et al. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs. 2005. Peer-reviewed study
- Klarskov P, Andersen AN, Trokmar M. [Goserelin]. Ugeskr Laeger. 1990. Peer-reviewed study
- Brogden RN, Faulds D. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs Aging. 1995. Peer-reviewed study
- Perry CM, Brogden RN. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Drugs. 1996. Peer-reviewed study
- Wojciechowski NJ, Carter CA, Skoutakis VA, et al. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm. 1986. Peer-reviewed study
- Ko YH, Ha YR, Kim JW, et al. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist leuprolide on androgen-independent prostate cancer (DU145). J Int Med Res. 2011. Peer-reviewed study
- Wilson AC, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007. Peer-reviewed study
- Teutonico D, Montanari S, Ponchel G. Leuprolide acetate: pharmaceutical use and delivery potentials. Expert Opin Drug Deliv. 2012. Peer-reviewed study
- Van Gerpen JA, McKinley KL. Leuprolide-induced myopathy. J Am Geriatr Soc. 2002. Peer-reviewed study
- Cox MC, Scripture CD, Figg WD. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. Expert Rev Anticancer Ther. 2005. Peer-reviewed study